尽管联邦批准,但禁毒局在2025年仍面临对阻碍医疗大麻获取的失败的审查。 DEA faces scrutiny in 2025 over failures hindering medical cannabis access, despite federal approvals.

2025年10月,缉毒局因关于系统失灵、道德行为失检和妨碍大麻医学研究的指控受到严密审查,调查前官员的行为包括未经授权的法律做法、不发照合同以及维持一个违宪的内部法庭。 The DEA is under intense scrutiny in October 2025 over allegations of systemic failures, ethical misconduct, and obstruction of medical cannabis research, with former officials investigated for actions including unauthorized legal practice, no-bid contracts, and upholding an unconstitutional in-house tribunal. 批评者说,尽管联邦批准,但这些行动延缓了病人获得以大麻为基础的治疗的机会,特别是那些患有亨廷顿病和多发性硬化症的人。 Critics say these actions delayed patient access to cannabis-based treatments, particularly for those with Huntington’s Disease and Multiple Sclerosis, despite federal approvals. 虽然该机构坚持其对执法和科学的承诺,但内部文件和法律裁决表明问责失败现象普遍存在。 While the agency maintains its commitment to law enforcement and science, internal documents and legal rulings suggest widespread accountability failures. 随着调查工作的继续和领导层的改变,倡导者希望改革将恢复透明度并加快获得联邦批准的治疗。 As investigations continue and leadership changes, advocates hope reforms will restore transparency and accelerate access to federally approved therapies.